1
|
Yuen ES, Sims JR. How predictive are photosensitive epilepsy models as proof of principle trials for epilepsy? Seizure 2014; 23:490-3. [DOI: 10.1016/j.seizure.2014.03.011] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2014] [Revised: 03/04/2014] [Accepted: 03/19/2014] [Indexed: 11/26/2022] Open
|
2
|
Zou X, Wu B, Yuan T. Progabide add-on for refractory epilepsy. Hippokratia 2012. [DOI: 10.1002/14651858.cd010158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- Xiaoyi Zou
- West China Hospital, Sichuan University; Department of Neurology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041
| | - Bo Wu
- West China Hospital, Sichuan University; Department of Neurology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041
| | - Tingting Yuan
- West China Hospital, Sichuan University; Department of Neurology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041
| |
Collapse
|
3
|
Abstract
Great progress has been made in the last 150 years in the pharmacological management of epilepsy, and, despite the increasing number of technological advances available, antiepileptic drugs (AEDs) remain the mainstay of treatment for the vast majority of patients with epilepsy. This review looks at possible avenues of development in the drug treatment of epilepsy. The strengths and weaknesses of those AEDs which are currently licensed are examined, and ways in which their use may be improved are discussed (e.g. rational combinations, use of new formulations). Potentially new targets that may allow the development of effective treatments are highlighted (neuroimmunological manipulation, decreasing inherent drug resistance mechanisms, and modification of adenosine neurotransmission), and a summary of the most promising AEDs currently in development is provided [e.g. carabersat, ganaxolone, harkoseride, MDL 27192, safinamide (NW 1015), pregabalin, retigabine, talampanel, valrocemide, losigamone and BIA 2093].
Collapse
Affiliation(s)
- A Nicolson
- Walton Centre for Neurology and Neurosurgery, Liverpool, UK
| | | |
Collapse
|
4
|
Fisher R, Blum D. Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs. Epilepsia 1995; 36 Suppl 2:S105-14. [PMID: 8784219 DOI: 10.1111/j.1528-1157.1995.tb05993.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Clinical investigators recently have studied at least 21 new antiepileptic drugs (AEDs) in people with epilepsy. This review briefly examines 15 of these new AEDs: clobazam (CLB), dezinamide, flunarizine (FNR), loreclezole, milacemide (MLM), MK-801, nafimidone, ORG-6370, oxcarbazepine (OCBZ), progabide (PGB), ralitoline, stiripentol, tiagabine (TGB), topiramate (TPM), and zonisamide (ZNS). CLB, PGB, and TGB represent agents that act on the GABA system, and MLM acts on the glycine system. MK-801 and ZNS (in part) are excitatory amino acid antagonists, and FNR is a calcium-channel antagonist. OCBZ is a keto analogue of carbamazepine, which is not metabolized to the epoxide and may have fewer side effects. The remaining agents are novel compounds with a variety of suspected mechanisms. TPM appears especially effective for intractable partial seizures but has a high incidence of cognitive side effects. None of these new AEDs is useful for all patients with inadequate seizure control or ongoing toxicity. The role of each will require further clinical study and experience.
Collapse
Affiliation(s)
- R Fisher
- Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013-4496, USA
| | | |
Collapse
|
5
|
de Pasquet EG, Scaramelli A, de Cáceres MP, L'Héritier C, Feldman S, Santana R, Aguilar J, Musch B, Morselli PL. Double-blind, placebo-controlled, cross-over trial of progabide as add-on therapy in epileptic patients. Epilepsia 1991; 32:133-9. [PMID: 1985823 DOI: 10.1111/j.1528-1157.1991.tb05625.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
In a double-blind, cross-over trial, progabide (PGB) and placebo were compared as add-on therapy in 59 patients with moderate to severe epilepsy. Eight patients did not complete the study, 4 because of adverse drug reactions (elevation of liver transaminases, 2; gastritis, 1; and acute psychosis, 1) and 4 because of administrative reasons. Among the remaining 51 patients, seizure frequency was reduced greater than 50% in 18 patients with PGB treatment and in 8 patients with placebo (p less than 0.05). The number of days with seizures was significantly (p = 0.034) reduced during PGB treatment. Both patients' and physicians' preferences at the end of the trial were in favor (p less than 0.01) of PGB. Mild clinical side effects were present in 54.7% of the patients treated with PGB and in 37.7% with placebo. Increase in liver transaminases was observed in 2 patients during the double-blind study and in 1 during the follow-up period. Our data show that PGB, as previously reported, is useful in 30-40% of patients who are not responding completely to other antiepileptic drugs (AEDs). The compound is well tolerated, but liver function must be monitored.
Collapse
Affiliation(s)
- E G de Pasquet
- Instituto de Neurología Hospital de Clínicas "Dr. Manuel Quintela," Montevideo, Uruguay
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Sato K, Morimoto K, Okamoto M, Nakamura Y, Otsuki S, Sato M. An analysis of anticonvulsant actions of GABA agonists (progabide and baclofen) in the kindling model of epilepsy. Epilepsy Res 1990; 5:117-24. [PMID: 2158438 DOI: 10.1016/0920-1211(90)90027-s] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The anticonvulsant action of progabide, an agonist of gamma-aminobutyric acid (GABA)A and GABAB receptors, was investigated in the kindling model of epilepsy in rats. Progabide shortened afterdischarge durations and attenuated the severity of the accompanying convulsive responses in previously kindled rats from the amygdala (AM), frontal cortex (FC), ventral and dorsal hippocampus (HIPP), in a dose-dependent manner. Although progabide was less effective in the dorsal HIPP kindled seizures, the efficacy was potent in AM, FC and ventral HIPP kindled seizures. On the other hand, the anticonvulsant action of baclofen, a selective agonist of GABAB receptors, was relatively weak in terms of the measurement of the afterdischarge duration of AM and HIPP kindled seizures even at toxic doses, compared with progabide. In addition, the anticonvulsant effects of progabide were partially reversed by treatment with the antagonist of benzodiazepine receptors, Ro 15-1788, whereas Ro 15-1788 administration alone did not alter AM kindled seizures. We concluded that the action of progabide may be mediated via the GABA/benzodiazepine receptor complex. These results support the hypothesis that a failure of GABAA-mediated inhibition is one of the bases of induction and generalization of seizures.
Collapse
Affiliation(s)
- K Sato
- Department of Neuropsychiatry, Okayama University Medical School, Japan
| | | | | | | | | | | |
Collapse
|
7
|
Chesnut TJ, Swann JW. Suppression of 4-aminopyridine-induced epileptogenesis by the GABAA agonist muscimol. Epilepsy Res 1990; 5:8-17. [PMID: 2303024 DOI: 10.1016/0920-1211(90)90061-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Bath application of muscimol to hippocampal slices taken from immature rats suppressed both spontaneous and electrically evoked epileptiform activity produced by 4-aminopyridine (4-AP). Epileptiform events consisted of ictal-like discharges that were up to 30 sec in duration and interictal burst-like discharges. The latter were often followed by brief synchronized afterdischarges that were less than 1 sec in duration. During the transition period to suppression, individual pyramidal cells did not hyperpolarize in response to muscimol, but instead underwent a gradual depolarization that averaged 8.5 mV. At the same time, the input conductance of these cells increased 2-3-fold. Concurrently the ictal-like discharges transiently increased in duration and then abruptly ceased. In most instances the ictal-like events were replaced by large slow depolarizing events. Orthodromic stimulation recruited these slow depolarizations in a graded manner. However, at high stimulus intensities and at unusually long latencies ictal-like discharges were evoked. This suggests that muscimol raises the threshold for the generation of ictal-like discharges but leaves the underlying physiological processes intact. The combined use of 4-AP and muscimol in immature hippocampal slices may prove to be useful for the study of the various physiologic processes that contribute to the genesis of seizures in immature hippocampus. In addition, results of these studies are relevant in light of the proposed use of GABA agonists in anticonvulsant therapy.
Collapse
Affiliation(s)
- T J Chesnut
- Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany 12201-0509
| | | |
Collapse
|
8
|
Abstract
Bath application of muscimol (10-20 microM) to hippocampal slices obtained from rats on postnatal days 10-15 produced epileptiform activity in the form of multiple population spikes in 20% of slices tested, concurrent with marked disinhibition. The disinhibition occurred in nearly 100% of cases tested at muscimol concentrations that produced epileptiform activity. Paired pulse analysis of GABAergic recurrent inhibition revealed a muscimol-induced disinhibitory effect involving a decrease in maximum possible inhibition. Spontaneous and antidromically elicited inhibitory postsynaptic potentials (IPSPs) recorded intracellularly were suppressed by muscimol. Current-voltage analysis of the recurrent IPSPs suggests that muscimol acted at a number of sites to produce disinhibition. The input conductance of the postsynaptic pyramidal cell increased due to muscimol, creating a current shunt which likely decreased the efficacy of synaptic currents. Muscimol also caused a decrease in the conductance due to the IPSP as well as a shift in the depolarizing direction of the equilibrium potential of the IPSP. The data indicate that muscimol, a GABAA agonist, can produce disinhibition resulting from the multiple consequences of its action. We conclude that the physiologic consequences of GABAA agonist treatment are complex. On the other hand, neurons are likely to be inhibited by a tonic increase in membrane conductance. However, since recurrent inhibition is simultaneously compromised, excitatory vollies of sufficient intensity may overcome the tonic inhibition and produce a hyperexcitable state. In some cases, this disinhibition may induce epileptiform activity. These observations are relevant in light of the proposed use of GABA agonists clinically to control seizures.
Collapse
Affiliation(s)
- T J Chesnut
- Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany 12201-0509
| | | |
Collapse
|
9
|
Munoz SJ, Fariello R, Maddrey WC. Submassive hepatic necrosis associated with the use of progabide: a GABA receptor agonist. Dig Dis Sci 1988; 33:375-80. [PMID: 3342728 DOI: 10.1007/bf01535765] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Progabide, a recently introduced gamma-aminobutyric acid mimetic, is currently undergoing clinical evaluation for a variety of convulsive disorders. We describe a patient in whom severe hepatic failure developed after four weeks of Progabide therapy. The patient's course was marked by encephalopathy, jaundice, hypoglycemia, markedly elevated serum aminotransferase levels, and prolongation of the prothrombin time. Liver biopsy showed extensive hepatocellular necrosis. The patient recovered slowly after discontinuation of the drug. The finding of eosinophilia and increased serum IgE suggests an immunologically mediated mechanism for the Progabide-induced hepatic injury. Alternatively, the lipophilic moiety of Progabide may interact with hepatocyte cell membrane lipids leading to toxic injury. We conclude that Progabide may occasionally cause severe hepatic injury.
Collapse
Affiliation(s)
- S J Munoz
- Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania 19107
| | | | | |
Collapse
|
10
|
Abstract
Ten patients suffering from absence epilepsy and showing generalized spike-wave paroxysms in the EEG were treated by progabide monotherapy. Findings concerning clinical data and serial 24 h long-term EEG recordings were compared for the pre-treatment and treatment period. The average total spike-wave duration in 24 h decreased slightly from 810 sec to 699 sec; at follow-up, in 4 cases this trend was found to have reversed. Concerning seizure frequency, a marked anticonvulsant effect could not be confirmed; an initial slight anti-absence activity in some cases seemed to be subjected to the development of tolerance. Side effects were rarely observed and if so were not severe.
Collapse
Affiliation(s)
- H Stefan
- Universitäts-Nervenklinik und Poliklinik/Epileptologie, University of Bonn, F.R.G
| | | | | | | | | |
Collapse
|
11
|
Bianchetti G, Padovani P, Thénot JP, Thiercelin JF, Morselli PL. Pharmacokinetic interactions of progabide with other antiepileptic drugs. Epilepsia 1987; 28:68-73. [PMID: 3098557 DOI: 10.1111/j.1528-1157.1987.tb03625.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The influence of progabide, a new antiepileptic drug, on the pharmacokinetic profiles of phenobarbital, phenytoin, carbamazepine, and valproic acid was evaluated in four separate studies, each including six young healthy volunteers. The pharmacokinetic parameters of the associated antiepileptic drugs were measured before and after repeated administration of progabide (600 mg t.i.d.) for 15 days. A significant reduction of the total body clearance of both phenytoin and phenobarbital and a higher Cmax value of carbamazepine epoxide and phenobarbital were observed. No modifications were noticed for the kinetic profiles of carbamazepine and valproic acid. These modifications may be of clinical relevance and suggest that, as a general rule, when progabide is added to an established treatment with phenobarbital or phenytoin or carbamazepine, an adjustment of previous posology may be necessary.
Collapse
|
12
|
Crawford P, Chadwick D. A comparative study of progabide, valproate, and placebo as add-on therapy in patients with refractory epilepsy. J Neurol Neurosurg Psychiatry 1986; 49:1251-7. [PMID: 3098923 PMCID: PMC1029073 DOI: 10.1136/jnnp.49.11.1251] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
A three way single blind cross-over comparison of progabide, valproate and placebo, as adjunctive therapy, was undertaken in 64 patients with therapy-resistant partial and generalised seizures. The study was not completed because of the incidence of elevated hepatic enzymes on progabide. Analysis of efficacy showed progabide to be inferior to valproate against all seizure types, particularly against tonic-clonic seizures. Valproate was superior to placebo against all seizure types, partial and tonic-clonic seizures. Progabide did not differ significantly from placebo in any instance. In addition progabide caused elevation of hepatic enzymes which was symptomatic in one case, and was associated with an interaction with phenytoin which resulted in symptoms of intoxication in some cases.
Collapse
|
13
|
Abstract
The effect of the experimental antiepileptic gamma-aminobutyric acid (GABA) agonist drug progabide, [alpha-(chloro-4-phenyl)fluor-5-hydroxy-2-benzilideneamino]-4-buty ramide, on the trigeminal complex of cats was compared with the effect of established antiepileptic drugs and with the effect of various GABA agonists and antagonists. Intravenous administration of 10-40 mg/kg progabide depressed excitatory transmission and descending periventricular inhibition, similar to carbamazepine and phenytoin. However, progabide depressed, rather than facilitated, segmental inhibition. The serum levels of progabide were comparable with those in patients receiving long-term treatment with progabide. The GABA antagonist bicuculline had the opposite effect of progabide on our experimental model, but the other GABA agonists THIP (4,5,6,7-tetrahydroisoxazolo-5,4-C-pyridine-3-ol) and muscimol did not have the same effects as progabide. THIP had no effect on excitatory transmission, periventricular inhibition, or segmental inhibition, whereas muscimol facilitated periventricular inhibition and sometimes segmental inhibition and had no effect on excitatory transmission. Our experiments thus indicate that progabide, but not THIP or muscimol, should have antiepileptic properties, in agreement with the clinical experiences that have been reported. The reason for the differential effect of these three GABA agonists remains to be elucidated.
Collapse
|
14
|
Abstract
The present paper reviews gas and liquid chromatographic methods for the determination of the most commonly monitored antiepileptic drugs: phenobarbital, phenytoin, carbamazepine, primidone, ethosuximide, valproic acid and clonazepam along with a new compound, progabide. The individual classes of drugs are first treated separately to highlight specific aspects of their quantification, and this is followed by an overview of those methods permitting the concomitant analysis of two or more antiepileptic compounds. Sample preparation techniques as well as comparisons between chromatographic and other techniques are treated more fully in separate sections.
Collapse
|